Evidence map›Paper›PMID 38453411›Full record

Trial reportAJNR. American journal of neuroradiology2024

Comparison of Volumetric and 2D Measurements and Longitudinal Trajectories in the Response Assessment of

Divya Ramakrishnan, Sarah C Brüningk, Marc von Reppert, Fatima Memon, Nazanin Maleki, Sanjay Aneja, Anahita Fathi Kazerooni, Ali Nabavizadeh, MingDe Lin, Khaled Bousabarah and 5 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial
In one paragraph

Trial report in AJNR. American journal of neuroradiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01748149 (Pediatric Neuro-Oncology Consortium), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01748149 early_phase1completednot on this map

Pediatric Neuro-Oncology Consortium (PNOC)-002: Safety, Phase 0, and Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children and Young Adults With Recurrent/Refractory BRAFV600E- or BRAF Ins T Mutant Brain Tumors

TypeinterventionalSponsorUniversity of California, San FranciscoRan2014 to 2025Enrolled40ConditionsPediatric Recurrent/Refractory BRAFV600E-mutant GliomasArmsVemurafenib
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 4 countries.

Divya RamakrishnanFrom the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut divya.ramakrishnan@yale.edu.ORCID 0000-0003-2581-1793
Sarah C BrüningkDepartment of Biosystems Science and Engineering (S.C.B.), ETH Zürich, Basel, Switzerland.
Marc von ReppertFrom the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0003-4623-7401
Fatima MemonFrom the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.
Nazanin MalekiFrom the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.
Sanjay AnejaDepartment of Therapeutic Radiology (S.A.), Yale School of Medicine, New Haven, CT, USA.ORCID 0000-0001-5681-7528
Anahita Fathi KazerooniCenter for Biomedical Image Computing and Analytics (A.F.K.), University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-7131-2261
Ali NabavizadehCenter for Data-Driven Discovery in Biomedicine (A.N.), Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.ORCID 0000-0002-0380-4552
MingDe LinFrom the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0001-7641-2595
Khaled BousabarahVisage Imaging (K.B.), Berlin, Germany.
Annette MolinaroDepartment of Neurological Surgery (A.M.), University of California San Francisco, San Francisco, Calfornia.
Theodore NicolaidesCaris Life Sciences (T.N.), Irving, Texas.
Michael PradosDepartment of Neurology (M.P., S.M.), Neurosurgery, and Pediatrics, University of California San Francisco, San Francisco, Calfornia.ORCID 0000-0002-9630-2075
Sabine MuellerDepartment of Neurology (M.P., S.M.), Neurosurgery, and Pediatrics, University of California San Francisco, San Francisco, Calfornia.ORCID 0000-0002-3452-5150
Mariam S AboianFrom the Department of Radiology and Biomedical Imaging (D.R., M.v.R., F.M., N.M., M.L., M.S.A.), Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-4877-8271
Yale University · USUniversity of California, San Francisco · USCaris Life Sciences (United States) · USChildren's Hospital of Philadelphia · USLaboratoire d’Imagerie Biomédicale · FRSage Technologies (United States) · USSIB Swiss Institute of Bioinformatics · CHYale New Haven Hospital · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Institutional Career Development CoreKL2TR001862 · NCATS · YALE UNIVERSITY · PI CANTLEY, LLOYD G, EDELMAN, E. JENNIFER · 2016 to 2025
$12.2M
NCATS NIH HHS KL2 TR001862NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

background and purposeResponse on imaging is widely used to evaluate treatment efficacy in clinical trials of pediatric gliomas. While conventional criteria rely on 2D measurements, volumetric analysis may provide a more comprehensive response assessment. There is sparse research on the role of volumetrics in pediatric gliomas. Our purpose was to compare 2D and volumetric analysis with the assessment of neuroradiologists using the Brain Tumor Reporting and Data System (BT-RADS) in MATERIALS AND

methodsManual volumetric segmentations of whole and solid tumors were compared with 2D measurements in 31 participants (292 follow-up studies) in the Pacific Pediatric Neuro-Oncology Consortium 002 trial (NCT01748149). Two neuroradiologists evaluated responses using BT-RADS. Receiver operating characteristic analysis compared classification performance of 2D and volumetrics for partial response. Agreement between volumetric and 2D mathematically modeled longitudinal trajectories for 25 participants was determined using the model-estimated time to best response.

resultsOf 31 participants, 20 had partial responses according to BT-RADS criteria. Receiver operating characteristic curves for the classification of partial responders at the time of first detection (median = 2 months) yielded an area under the curve of 0.84 (95% CI, 0.69-0.99) for 2D area, 0.91 (95% CI, 0.80-1.00) for whole-volume, and 0.92 (95% CI, 0.82-1.00) for solid volume change. There was no significant difference in the area under the curve between 2D and solid (

conclusionsAlthough there was no overall difference between volumetrics and 2D in classifying partial response assessment using BT-RADS, further prospective studies will be critical to elucidate how the observed differences in tumor 2D and volumetric trajectories affect clinical decision-making and outcomes in some individuals.

Indexed as

Brain NeoplasmsGliomaChildHumansMagnetic Resonance ImagingProspective StudiesProto-Oncogene Proteins B-rafTreatment OutcomeBRAF protein, humanProto-Oncogene Proteins B-raf

Identifiers

PMID38453411
PMCPMC11288571
OpenAlexW4392545565

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.